Screener
Perspective Therapeutics CATX Total Revenue
Discontinued — last reported Q3 '23
Total Revenue at other companies
Other financials
Where this comes from
Reported directly by Perspective Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Perspective Therapeutics’s 10-Q, filed November 14, 2023.
- Filed
- Nov 14, 2023, 4:59 PM EST
- Fiscal quarter
- Q3 FY2023
- Calendar quarter
- Q3 2023
- Accession
- 0001437749-23-032036
| Line item | Three months ended / September 30, 2023 | Three months ended / September 30, 2022 | Nine months ended / September 30, 2023 | Nine months ended / September 30, 2022 |
|---|---|---|---|---|
| Sales, net | $1,909 | $$1,717 | $5,239 | 7,132 |
| Grant revenue | 276 | - | 1,097 | - |
| Total revenue | 2,185 | 1,717 | 6,336 | 7,132 |
| Cost of sales | 1,447 | 1,303 | 4,863 | 4,351 |
| Gross profit | 738 | 414 | 1,473 | 2,781 |
| Operating expenses: | ||||
| Research and development | 5,721 | 708 | 15,231 | 2,053 |
| Sales and marketing | 855 | 800 | 2,578 | 2,141 |
ITEM 1 - FINANCIAL STATEMENTS
FAQ
- What is Perspective Therapeutics's total revenue?
- Perspective Therapeutics (CATX) reported total revenue of $2.19M in Q3 2023.
- How has Perspective Therapeutics's total revenue changed year-over-year?
- Perspective Therapeutics's total revenue increased by 27.3% year-over-year, from $1.72M to $2.19M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Perspective Therapeutics's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude